“Bausch Health is off to a strong start in 2019 with the continued growth of XIFAXAN which grew 11% in the quarter, the launch of BRYHALI, the successful acquisition of TRULANCE, and the approval of DUOBRII and expected launch in June. We believe that our promising pipeline and focus on Project CORE has positioned the company to build on our growth in 2019 and beyond. Strong operational execution is leading us to raise our full-year 2019 revenue and adjusted EBITDA guidance,” said Joseph Papa, chairman and CEO, Bausch Health. “With nearly 60% of our revenues coming from a diversified mix of medical devices, OTC products and prescription and branded generic products that are not exposed to the U.S. branded prescription drug pricing environment, we believe that Bausch Health is uniquely positioned to grow in health care,” Papa continued.
Monday, May 6, 2019
Cytokinetics price target raised to $26 from $21 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $26 from $21 and keeps a Buy rating on the shares. While the Phase 2 trial testing reldesemtiv in patients with amyotrophic lateral sclerosis missed its endpoint misses, reldesemtiv activity was “clear and broad,: setting up the next steps, Pantginis tells investors in a research note titled “Bad Headline, Impressive Data; Reldesemtiv Effects Consistent; Target Increased to $26.” The analyst believes the data show important characteristics of reldesemtiv, including comparable effects across all doses, consistent effects across all timepoints, and durability of the effects.
Adaptimmune announces clinical progress in ADP-A2M4 study
Adaptimmune announced clinical progress with partial responses in 4 out of 5 synovial sarcoma patients treated with 10B cells in the ADP-A2M4 pilot study and tumor shrinkage seen in nearly all assessed synovial sarcoma patients. Based on these data, the company will initiate the SPEARHEAD-1 trial in patients with synovial sarcoma and myxoid/round cell liposarcoma, or MRCLS, later this year. Beyond sarcoma, there is evidence of antitumor activity with ADP-A2M4 and ADP-A2M10 in other solid tumors. Based on these data and translational findings, the company is expanding its clinical trial program by initiating a radiation sub-study, as well as opening a next-generation ADP-A2M4CD8 study, for which the IND has been filed. Finally, the first patient with HCC was treated in Cohort 2 of the ADP-A2AFP study and showed tolerability to treatment and a transient decrease in serum AFP as well as tumor shrinkage at first scan. ADP-A2M4 SPEAR T-cells appear to show a favorable benefit:risk profile in patients with synovial sarcoma with “good” tolerability overall. Most adverse events are consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies. Tumor shrinkage seen in lung patients in ADP-A2M10 and melanoma and ovarian patients in ADP-A2M4. Adaptimmune is planning to start two new studies to transform currently observed activity in epithelial tumors into durable responses.
https://thefly.com/landingPageNews.php?id=2903577
https://thefly.com/landingPageNews.php?id=2903577
Insulet price target raised to $110 from $100 at Canaccord
Canaccord analyst Kyle Rose raised his price target for Insulet to $110 from $100 and maintained a Buy rating following last week’s Q1 earnings report. In a research note to investors following the earnings report, Rose said he continues to believe Insulet is positioned favorably ahead of what he views as a compelling new product cycle in Dash.
https://thefly.com/landingPageNews.php?id=2903583
https://thefly.com/landingPageNews.php?id=2903583
STAAR Surgical price target lowered to $38 from $43 at Canaccord
Canaccord analyst Jason Mills lowered his price target for STAAR Surgical to $38 from $43, saying he recommends adding to positions, notwithstanding the uncertainty around the timing of EVO ICL approval in the U.S. Mills tells investors in a research note that he came away from a meeting with ophthalmologists, industry consultants and STAAR management at the American Society of Cataract & Refractive Surgeons meeting this weekend “confident” in the firm’s near- and long-term ICL growth potential. Mills maintains a Buy rating.
https://thefly.com/landingPageNews.php?id=2903587
https://thefly.com/landingPageNews.php?id=2903587
Omeros initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated Omeros with an Outperform and $26 price target
Boston Scientific Gets U.S. FDA Approval for The VICI VENOUS STENT System
Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.
Venous obstructive disease affects nearly 40 percent of the population in the U.S. and can be caused by conditions such as deep vein thrombosis (DVT), post-thrombotic syndrome (PTS) and compressive diseases such as May-Thurner syndrome. In patients with venous obstructions, blood may pool in the legs, resulting in pain, swelling and skin ulcers.
Endovascular treatment for venous obstructive disease is focused on restoring the normal flow of blood from the legs back to the heart. The iliofemoral veins are located deep in the pelvis and may be subject to significant crushing forces from other anatomical structures such as the right common iliac artery. To help solve for this, the VICI stent system was specifically designed to be uniformly strong and crush resistant, capable of restoring blood blow by creating a cylindrical, patent vessel.
Subscribe to:
Comments (Atom)